{"nctId":"NCT01246791","briefTitle":"Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers","startDateStruct":{"date":"2010-11"},"conditions":["Healthy"],"count":12,"armGroups":[{"label":"NPC-01","type":"EXPERIMENTAL","interventionNames":["Drug: NPC-01"]}],"interventions":[{"name":"NPC-01","otherNames":["Norethisterone and Ethinyl Estradiol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy female aged between 20 to 35 years\n* BMI:18.0-26.0\n\nExclusion Criteria:\n\n* Females who are pregnant\n* Drug use affecting sex hormone secretion","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"20 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of area under the plasma concentration versus time curve (AUC) of norethisterone that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.183","spread":"36.316"}]}]}]},{"type":"PRIMARY","title":"Area Under the Plasma Concentration Versus Time Curve (AUC) on Ethinyl Estradiol of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of area under the plasma concentration versus time curve (AUC) of ethinyl estradiol that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"368.123","spread":"170.882"}]}]}]},{"type":"PRIMARY","title":"Peak Plasma Concentration (Cmax) on Norethisterone of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of peak plasma concentration (Cmax) of norethisterone that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.481","spread":"6.205"}]}]}]},{"type":"PRIMARY","title":"Peak Plasma Concentration (Cmax) on Ethinyl Estradiol of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of peak plasma concentration (Cmax) of ethinyl estradiol that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.783","spread":"17.201"}]}]}]},{"type":"PRIMARY","title":"Time to Peak Plasma Concentration (Tmax) on Norethisterone of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of time to peak plasma concentration (Tmax) of norethisterone that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"0.79"}]}]}]},{"type":"PRIMARY","title":"Time to Peak Plasma Concentration (Tmax) on Ethinyl Estradiol of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of time to peak plasma concentration (Tmax) of ethinyl estradiol that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"0.43"}]}]}]},{"type":"PRIMARY","title":"Plasma Half Life (t1/2) on Norethisterone of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of plasma Half life (t1/2) of norethisterone that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.357","spread":"1.863"}]}]}]},{"type":"PRIMARY","title":"Plasma Half Life (t1/2) on Ethinyl Estradiol of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of plasma Half life (t1/2) of ethinyl estradiol that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.499","spread":"2.207"}]}]}]},{"type":"PRIMARY","title":"Mean Residence Time (MRT) on Norethisterone of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of mean residence time (MRT) of norethisterone that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.340","spread":"0.459"}]}]}]},{"type":"PRIMARY","title":"Mean Residence Time (MRT) on Ethinyl Estradiol of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of mean residence time (MRT) of ethinyl estradiol that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.161","spread":"1.504"}]}]}]},{"type":"PRIMARY","title":"Elimination Rate Constant (Kel) on Norethisterone of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of elimination rate constant (kel) of norethisterone that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.101","spread":"0.029"}]}]}]},{"type":"PRIMARY","title":"Elimination Rate Constant (Kel) on Ethinyl Estradiol of NPC-01","description":"Multiple blood samples will obtains at pretreatment(0 hour), 0.5, 1.0, 1.5, 2.0, 4.0, 6.0, 9.0, 12.0 and 24.0 hours after dosing of NPC-01(1mg norethisterone and 0.02mg ethinyl estradiol) and determination of elimination rate constant (kel) of ethinyl estradiol that are active substances of NPC-01.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.141","spread":"0.043"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Metrorrhagia","Headache","Blood iron decreased","White blood cell count decreased"]}}}